Skip to content

Serotonin: all studies

Page 260 of 401: studies 2,591 to 2,600 of 4,004, newest first. Back to the serotonin overview

Research

LSD and psilocybin for chronic nociplastic pain: A narrative review of the literature supporting the use of classic psychedelic agents in chronic pain.

South African Medical Journal November 6, 2023 J Van Der Walt, R Parker 3 citations

Healthcare providers face the challenging task of managing patients who suffer from chronic nociplastic pain conditions. Pain is a multidimensional experience, and the current approach to managing people in chronic pain often fails to meet the needs of these patients. Novel ways of treating people who suffer from chronic nociplastic pain with classic psychedelic agents may offer a new lens...

DOI: 10.7196/samj.2023.v113i11.814 (opens in new tab) Full text (opens in new tab) Psychedelics Chronic pain treatment Alternative medicine Pain management

PSICOTERAPIA ASSISTIDA POR PSILOCIBINA PARA TRATAMENTO DE DEPRESSÃO E ANSIEDADE EM PACIENTES COM CÂNCER EM RISCO DE VIDA: UMA REVISÃO DE LITERATURA

RECIMA21 - Revista Científica Multidisciplinar - ISSN 2675-6218 November 5, 2023 Sara Almeida Oliveira, Victor Augusto Rodovalho Fava

A psilocibina é o princípio ativo dos cogumelos da espécie Psilocybe cubensis, historicamente conhecidos como cogumelos mágicos. É um agonista dos receptores serotoninérgicos 5HT2A. O seu uso para o tratamento do transtorno de ansiedade generalizada e da depressão em indivíduos com câncer em estágio terminal apresenta resultados promissores em ensaios clínicos. Objetivo: Revisão da literatura...

MDMA-Based Psychotherapy in Treatment-Resistant Post-Traumatic Stress Disorder (PTSD): A Brief Narrative Overview of Current Evidence

Diseases November 3, 2023 Kainat Riaz, Sejal Suneel, Mohammad Hamza Bin Abdul Malik et al. 16 citations

Post-traumatic stress disorder (PTSD) is a debilitating mental health disorder that causes significant dysfunction in individuals. Currently, there are many approved pharmacotherapy and psychotherapy treatment options for PTSD, but unfortunately, half of the patients do not respond to traditional therapies. In this article, we review clinical trials and research on...

The effects of ketamine and methamphetamine on neurotransmitters, glutamate receptors, and conditioned place preference in rat.

Legal medicine (Tokyo, Japan) November 2023 Yanxia Peng, Yihang Wang, Linlin Liu et al.

Combined methamphetamine (MA) and ketamine (KET) abuse is a serious issue. At present, however, few studies have explored the mechanism underlying their combined addiction. We established a rat conditioned place preference (CPP) model. We investigated the role of dopamine (DA), 5-hydroxytryptamine (5-HT), monoamine oxidase (MAO), glutamate receptor 1 (GluR1), and glutamate receptor 2 (GluR2) in...

The potential of psychedelics for the treatment of Alzheimer's disease and related dementias.

European Neuropsychopharmacology November 1, 2023 Michael James Winkelman, Attila Szabo, Ede Frecska 26 citations

Alzheimer's Disease (AD) is a currently incurable but increasingly prevalent fatal and progressive neurodegenerative disease, demanding consideration of therapeutically relevant natural products and their synthetic analogues. This paper reviews evidence for effectiveness of natural and synthetic psychedelics in the treatment of AD causes and symptoms. The plastogenic effects of serotonergic...

Addiction specialists' attitudes toward psychedelics: A National Survey.

American Journal on Addictions November 1, 2023 Amanda Kim, Joji Suzuki 15 citations

In recent years, there has been accelerating scientific and public interest in the use of psychedelics to treat mental health disorders. Our study's objective was to assess the attitudes of addiction specialists regarding therapeutic psychedelics. Our study utilized an anonymous online survey to assess the opinions of 145 addiction specialists regarding the therapeutic promise, potential risks,...

UNRAVELing the synergistic effects of psilocybin and environment on brain-wide immediate early gene expression in mice.

Neuropsychopharmacology November 1, 2023 Daniel Ryskamp Rijsketic, Austen B Casey, Daniel A. N. Barbosa et al. 49 citations

The effects of context on the subjective experience of serotonergic psychedelics have not been fully examined in human neuroimaging studies, partly due to limitations of the imaging environment. Here, we administered saline or psilocybin to mice in their home cage or an enriched environment, immunofluorescently-labeled brain-wide c-Fos, and imaged iDISCO+ cleared tissue with light sheet...

Psychedelic Drugs or Hallucinogens: Exploring Their Medicinal Potential.

Cureus November 1, 2023 Priyanshu Raj, Shyambabu Rauniyar, Bhagyesh Sapkale 8 citations

Serotonergic hallucinogens also referred to as psychedelics, are psychoactive substances that profoundly alter perception, mood, and cognitive processes. These substances, historically intertwined with religious and cultural rituals, offer profound effects that extend beyond mere hallucinations to profoundly altered states of consciousness. Notable compounds like Lysergic acid diethylamide...

DOI: 10.7759/cureus.48719 (opens in new tab) Full text (opens in new tab) Hallucinogens uses Psychedelic drug research Psychedelic drugs Psychedelic medicines +4

‘’The Science Behind Raj Yoga Meditation-A Narrative Review’’

Advancement in Yoga and Physical Therapy October 31, 2023 2 citations

On invitation to write an article on Yoga here we decided to write on science of Raj yoga meditation (RM). Normally besides the classic asana-based meditations there are 3 kinds of meditations i) Contemplation/ Concentration based ii) Mindful based iii) Love kind of meditation. Despite so much scepticism the western world found results with meditation and according to them Mindful based...

Indirect adjusted comparison of 6-month clinical outcomes between esketamine nasal spray and other real-world polypharmacy treatment strategies for treatment resistant depression: results from the ICEBERG study

Frontiers in Psychiatry October 31, 2023 Albino J Oliveira-Maia, Benoit Rive, Joachim Morrens et al. 6 citations

BackgroundThe efficacy of esketamine nasal spray (NS) as a rapid-acting agent for treatment resistant depression (TRD) was demonstrated in comparisons with placebo, when both were given in addition to a newly initiated selective serotonin reuptake inhibitor (SSRI)/serotonin norepinephrine reuptake inhibitor (SNRI). How esketamine NS compares with commonly used real-world (RW) polypharmacy...

DOI: 10.3389/fpsyt.2023.1250987 (opens in new tab) Full text (opens in new tab) Esketamine nasal spray Treatment resistant depression Real-world evidence Indirect comparison +2